In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6528
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits ; volume:7 ; number:1 ; day:14 ; month:5 ; year:2018 ; pages:157-165 ; date:6.2018
Ophthalmology and therapy ; 7, Heft 1 (14.5.2018), 157-165, 6.2018
- Creator
-
Sheppard, John D.
- Contributor
-
Cockrum, Paul C.
Justice, Angela
Jasek, Mark C.
SpringerLink (Online service)
- DOI
-
10.1007/s40123-018-0130-1
- URN
-
urn:nbn:de:101:1-2018082111563462416890
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:29 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sheppard, John D.
- Cockrum, Paul C.
- Justice, Angela
- Jasek, Mark C.
- SpringerLink (Online service)
Other Objects (12)
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Lotilaner Ophthalmic Solution 0.25%: First Approval
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
Ophthalmic histopathology
Ophthalmic histopathology
Practical ophthalmic microsurgery
Ophthalmic surgical procedures
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
The physical, chemical, and microbiological stability of chloramphenicol ophthalmic solution
Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose
Viscoelastics in ophthalmic surgery
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Lotilaner Ophthalmic Solution 0.25%: First Approval
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
Ophthalmic histopathology
Ophthalmic histopathology
Practical ophthalmic microsurgery
Ophthalmic surgical procedures
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
The physical, chemical, and microbiological stability of chloramphenicol ophthalmic solution
Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose
Viscoelastics in ophthalmic surgery
Correction to: In Vivo Pharmacokinetics of Bromfenac Ophthalmic Solution 0.075%, Bromfenac Ophthalmic Solution 0.07%, and Nepafenac/Amfenac Ophthalmic Suspension 0.3% in Rabbits
Lotilaner Ophthalmic Solution 0.25%: First Approval
Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval
Ophthalmic histopathology
Ophthalmic histopathology
Practical ophthalmic microsurgery
Ophthalmic surgical procedures
Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
The physical, chemical, and microbiological stability of chloramphenicol ophthalmic solution
Bromfenac Ophthalmic Solution 0.07% Versus Nepafenac Ophthalmic Suspension 0.3% for Post-Cataract Surgery Inflammation: A Pilot Study of Identical Dosing Regimens with Pre-Surgical “Pulse” Dose